RS52423B - THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT - Google Patents

THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT

Info

Publication number
RS52423B
RS52423B RS20120327A RSP20120327A RS52423B RS 52423 B RS52423 B RS 52423B RS 20120327 A RS20120327 A RS 20120327A RS P20120327 A RSP20120327 A RS P20120327A RS 52423 B RS52423 B RS 52423B
Authority
RS
Serbia
Prior art keywords
crystalline form
agometaline
preparatin
pharmaceutical compositions
compositions containing
Prior art date
Application number
RS20120327A
Other languages
English (en)
Serbian (sr)
Inventor
Jean-Claude Souvie
Gérard Coquerel
Julie Linol
Original Assignee
Les Laboratoires Servier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36581629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS52423(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Les Laboratoires Servier filed Critical Les Laboratoires Servier
Publication of RS52423B publication Critical patent/RS52423B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
RS20120327A 2005-08-03 2006-08-02 THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT RS52423B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508278A FR2889523B1 (fr) 2005-08-03 2005-08-03 Nouvelle forme cristalline v de l'agomelatine, son procede de preparation et les compositions pharmaceutiques qui la contiennent

Publications (1)

Publication Number Publication Date
RS52423B true RS52423B (en) 2013-02-28

Family

ID=36581629

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20120327A RS52423B (en) 2005-08-03 2006-08-02 THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT

Country Status (37)

Country Link
EP (2) EP2277857A3 (enrdf_load_stackoverflow)
JP (1) JP4575337B2 (enrdf_load_stackoverflow)
CN (1) CN100448843C (enrdf_load_stackoverflow)
AP (1) AP2486A (enrdf_load_stackoverflow)
AR (1) AR057715A1 (enrdf_load_stackoverflow)
AU (1) AU2006203342B2 (enrdf_load_stackoverflow)
BR (1) BRPI0603059A (enrdf_load_stackoverflow)
CA (1) CA2555115C (enrdf_load_stackoverflow)
CR (1) CR8529A (enrdf_load_stackoverflow)
CU (1) CU20060153A7 (enrdf_load_stackoverflow)
CY (1) CY1113011T1 (enrdf_load_stackoverflow)
DK (1) DK1752443T3 (enrdf_load_stackoverflow)
EA (1) EA011030B1 (enrdf_load_stackoverflow)
EC (1) ECSP066715A (enrdf_load_stackoverflow)
ES (1) ES2391406T3 (enrdf_load_stackoverflow)
FR (1) FR2889523B1 (enrdf_load_stackoverflow)
GT (1) GT200600346A (enrdf_load_stackoverflow)
HR (1) HRP20120779T1 (enrdf_load_stackoverflow)
IL (1) IL177173A (enrdf_load_stackoverflow)
JO (1) JO2793B1 (enrdf_load_stackoverflow)
MA (1) MA28451B1 (enrdf_load_stackoverflow)
ME (1) ME02026B (enrdf_load_stackoverflow)
MX (1) MXPA06008789A (enrdf_load_stackoverflow)
MY (1) MY139902A (enrdf_load_stackoverflow)
NO (1) NO336967B1 (enrdf_load_stackoverflow)
NZ (1) NZ548864A (enrdf_load_stackoverflow)
PE (1) PE20070365A1 (enrdf_load_stackoverflow)
PL (1) PL1752443T3 (enrdf_load_stackoverflow)
PT (1) PT1752443E (enrdf_load_stackoverflow)
RS (1) RS52423B (enrdf_load_stackoverflow)
SA (1) SA06270255B1 (enrdf_load_stackoverflow)
SG (1) SG130110A1 (enrdf_load_stackoverflow)
SI (1) SI1752443T1 (enrdf_load_stackoverflow)
TW (1) TWI359128B (enrdf_load_stackoverflow)
UA (1) UA83720C2 (enrdf_load_stackoverflow)
WO (1) WO2007015004A2 (enrdf_load_stackoverflow)
ZA (1) ZA200606453B (enrdf_load_stackoverflow)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2934856B1 (fr) * 2008-08-05 2010-08-13 Servier Lab Nouveau procede d'obtention de la forme cristalline v de l'agomelatine
CN101481321B (zh) * 2009-02-27 2012-04-18 上海医药工业研究院 阿戈美拉汀卤化氢复合物及其制备方法
CN101585779B (zh) 2009-03-10 2014-04-02 上海医药工业研究院 阿戈美拉汀的晶型vi及其制备方法和应用
WO2011006387A1 (zh) * 2009-07-11 2011-01-20 浙江华海药业股份有限公司 阿戈美拉汀的制备方法、阿戈美拉汀晶形及其制备方法
CN102001959B (zh) * 2009-09-01 2014-07-02 北京本草天源药物研究院 一种药物晶体及其制备方法和用途
CN102050755B (zh) * 2009-10-29 2014-11-05 重庆医药工业研究院有限责任公司 阿戈美拉汀的晶型及其制备方法
CN101781226B (zh) 2009-12-23 2012-03-28 天津泰普药品科技发展有限公司 阿戈美拉汀及其药物组合物
EP2580183B1 (en) 2010-06-10 2014-07-23 Gador S.A. New process for the preparation of n-[2-(7-methoxy-1-naphthyl)-ethyl]acetamide
CN102000583B (zh) * 2010-11-18 2012-08-15 烟台万华聚氨酯股份有限公司 一种氯化氢氧化制氯气的催化剂及其制备方法
CN102690210A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物
CN102690209A (zh) * 2011-03-23 2012-09-26 上海医药工业研究院 阿戈美拉汀的混晶(形式-ⅷ)、其制备方法、应用和包含其的药物组合物
KR102135550B1 (ko) * 2011-06-02 2020-07-21 키노인 제트알티. 프로스타글란딘 아미드의 신규한 제조 방법
FR2978916B1 (fr) 2011-08-10 2013-07-26 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
ES2634243T3 (es) 2011-11-30 2017-09-27 Ratiopharm Gmbh Complejo de agomelatina-urea y formas cristalinas del mismo
CZ2012108A3 (en) 2012-02-15 2013-02-27 Zentiva Ks A method for the manufacture of a polymorphously stable pharmaceutical composition containing agomelatine
CN103360275B (zh) * 2012-03-30 2015-04-22 上海创诺制药有限公司 一种制备阿戈美拉汀ⅰ型晶体的方法
EP2934502A1 (en) 2012-12-21 2015-10-28 Laboratorios Lesvi S.L. Process for prepararing n-(2-(7-methoxy-1-naphthalenyl)ethyl) acetamide and solid forms thereof
FR3001894A1 (fr) 2013-02-08 2014-08-15 Servier Lab Composition pharmaceutique solide pour administration buccale d'agomelatine
EP2810647A1 (en) 2013-06-06 2014-12-10 Zentiva, a.s. Pharmaceutical formulations comprising agomelatine in the form of agomelatine co-crystal with an organic acid
HUE036989T2 (hu) 2013-06-06 2018-08-28 Zentiva Ks Agomelatin készítmény, amely agomelatint ko-kristály formájában tartalmaz
CZ2013621A3 (cs) 2013-08-13 2015-02-25 Zentiva, K.S. Termodynamicky stabilní tuhý roztok agomelatinu pro použití ve farmaceutické formulaci
WO2015124496A1 (en) 2014-02-19 2015-08-27 Synthon B.V. Pharmaceutical composition comprising amorphous agomelatine
FR3033131B1 (fr) 2015-02-26 2017-11-17 Servitronique Glissiere pour ses systemes de reglage coulissants et procede d'assemblage
ES2959460T3 (es) 2015-03-31 2024-02-26 Fis Fabbrica Italiana Sintetici Spa Forma sólida de agomelatina
EP3466923A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Process for the preparation of agomelatine in crystalline form
EP3466413A1 (en) 2017-10-09 2019-04-10 KRKA, d.d., Novo mesto Pharmaceutical composition containing agomelatine and process for the preparation thereof
CN113952323A (zh) * 2021-12-10 2022-01-21 李甜 阿戈美拉汀在抑制Ube2c蛋白表达中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2658818B1 (fr) * 1990-02-27 1993-12-31 Adir Cie Nouveaux derives a structure naphtalenique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
FR2866335B1 (fr) * 2004-02-13 2006-05-26 Servier Lab Nouveau procede de synthese de l'agomelatine
FR2866336B1 (fr) * 2004-02-13 2006-03-24 Servier Lab Nouveau procede de synthese du (7-methoxy-3,4-dihydro-1-naphtalenyl) acetonitrile et application a la synthese de l'agomelatine

Also Published As

Publication number Publication date
AP2006003695A0 (en) 2006-08-31
PT1752443E (pt) 2012-07-25
ES2391406T3 (es) 2012-11-26
CN100448843C (zh) 2009-01-07
CY1113011T1 (el) 2016-04-13
NO336967B1 (no) 2015-12-07
WO2007015004A3 (fr) 2007-03-22
CN1907958A (zh) 2007-02-07
ME02026B (me) 2012-11-06
CA2555115C (fr) 2013-12-10
HRP20120779T1 (hr) 2012-10-31
WO2007015004A2 (fr) 2007-02-08
MA28451B1 (fr) 2007-03-01
JO2793B1 (en) 2014-03-15
FR2889523A1 (fr) 2007-02-09
AP2486A (en) 2012-10-03
FR2889523B1 (fr) 2007-12-28
MY139902A (en) 2009-11-30
BRPI0603059A (pt) 2007-08-14
TWI359128B (en) 2012-03-01
HK1098128A1 (zh) 2007-07-13
EP1752443A1 (fr) 2007-02-14
ZA200606453B (en) 2007-12-27
AR057715A1 (es) 2007-12-12
EA011030B1 (ru) 2008-12-30
SI1752443T1 (sl) 2012-10-30
SA06270255B1 (ar) 2010-06-13
CA2555115A1 (fr) 2007-02-03
NZ548864A (en) 2008-03-28
UA83720C2 (ru) 2008-08-11
NO20063517L (no) 2007-02-05
AU2006203342B2 (en) 2012-07-19
PE20070365A1 (es) 2007-06-02
DK1752443T3 (da) 2012-10-22
EP1752443B1 (fr) 2012-07-11
PL1752443T3 (pl) 2012-11-30
GT200600346A (es) 2007-02-28
MXPA06008789A (es) 2007-02-02
EA200601273A1 (ru) 2007-02-27
ECSP066715A (enrdf_load_stackoverflow) 2007-03-29
EP2277857A2 (fr) 2011-01-26
JP4575337B2 (ja) 2010-11-04
TW200736199A (en) 2007-10-01
CR8529A (es) 2006-12-07
EP2277857A3 (fr) 2011-06-01
IL177173A (en) 2011-10-31
SG130110A1 (en) 2007-03-20
AU2006203342A1 (en) 2007-02-22
JP2007056017A (ja) 2007-03-08
IL177173A0 (en) 2006-12-10
CU20060153A7 (es) 2012-04-15

Similar Documents

Publication Publication Date Title
RS52423B (en) THE NEW CRYSTAL FORM OF AGOMELATIN, THE PROCEDURE FOR THE PRODUCTION OF IT AND THE PHARMACEUTICAL MIXTURES CONTAINING IT
TW200736197A (en) New crystalline form III of agomelatine, a process for its preparation and pharmaceutical compositions containing it
RS50915B (sr) α KRISTALNI OBLIK TERCIJALNE BUTILAMINSKE SOLI PERINDOPRILA
CO5780132A1 (es) Nueva forma cristalina y de la agomelatina, suprocedimiento de preparacion y las composiciones que las contienen
MX2008013782A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
AR046124A1 (es) Forma polimorfica de la n-[(r)-2,3-dihidroxipropoxi]-3,4 difluoro-2-(2-fluoro-4-iodofenilamino)benzamida; proceso de obtencion y composiciones farmaceuticas
RS50600B (sr) Kristalni oblik gama - d ivabradin hlorhidrata, postupak njegove izrade i farmaceutske smeše koje ga sadrže
MY138452A (en) Novel process for synthesizing and a novel crystal form of agomelatine as well as pharmaceutical preparations containing these
RS50661B (sr) Beta kristalni oblik ivabradin hidrohlorida, postupak njegove izrade i farmaceutske smeše koje ga sadrže
PH12014500947A1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
RS54754B1 (sr) Kristalni oblik argininske soli perindoprila, postupak njene proizvodnje i farmaceutske smeše koje je sadrže
MY141853A (en) 1-amino-2-oxy-substituted tetrahydronaphtalene derivatives, methods for the production thereof, and their use as antiphlogistics
MX2013000295A (es) Procedimiento de preparacion de un inhibidor especifico de la trombina.
MY204339A (en) Novel calcium salt polymorphs as anti-inflammatory, immunomodulatory and anti-proliferatory agents
NO20083506L (no) Beta-krystallinsk form av argininsaltet til perindopril, en prosess for dets fremstilling og farmasoytiske sammensetninger inneholdende dette
MX2020011671A (es) Nuevo proceso para la preparacion de diamidas antranilicas.
TW200716597A (en) Novel piperidine-substituted indoles
HRP20050352B1 (hr) Piperazinilni i diazepanilni benzamidi i benztioamidi
BRPI0916544A2 (pt) Rotas de síntese para 2(s), 4(s), 5(s), 7(s) - 2, 7 dialquil-4-hidroxi-2-amino-8-aril-octanoil amida
MY144746A (en) Process for the preparation of agomelatine
CA1084925A (en) Aminodi- and polyalkylamidoalkane sulfonic acids, process for their manufacture and their use
DE60331051D1 (de) Neue atorvastatinsalze und pharmazeutische zusammensetzungen, die diese enthalten
MD4350B1 (ro) Forma cristalină delta a sării de L-arginină a perindoprilului, procedeu de obţinere a ei şi compoziţii farmaceutice care o conţin
MX344965B (es) Preparacion de (r) y (s)-n-(3,4-difluoro-2-(2-fluoro-4-yodofenilam ino)-6-metoxifenil)-1-(2,3-dihidroxipropil)ciclopropan-1-sulfonam ida y derivados protegidos de los mismos.
MY140089A (en) Process for synthesizing (7-methoxy-1-naphthyl) acetonitrile and its application in the synthesis of agomelatine